Skip to content
Dosage GuideResearch Reference

NGF Mimetic Peptides Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for NGF Mimetic Peptides. All information is for educational purposes only.

Quick Answer

Dosage for NGF mimetic peptides varies widely depending on the specific compound (e.g., BB14, hNGFp) and the route of administration. Preclinical studies typically use doses ranging from micrograms to milligrams per kilogram of body weight. No standardized human dosing exists due to the experimental nature of these peptides. Subcutaneous, intranasal, and intravenous routes have been explored in animal models.

→ NGF Mimetic Peptides Benefits→ NGF Mimetic Peptides Side Effects→ Full NGF Mimetic Peptides Profile
Table of Contents

Standard Dosage Range

Research dosing range: Variable, dependent on specific peptide and study design. Preclinical ranges: mcg/kg to mg/kg

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Neuroprotection in Alzheimer's Models (hNGFp)

100–500 mcg/kg1× daily
Duration

4–12 weeks

Based on rodent studies. hNGFp has shown blood-brain barrier penetration. Route of administration in studies typically intraperitoneal, subcutaneous is a more practical research analog.

Neurite Outgrowth (BB14)

10–100 mcg/mLIn vitro or local application
Duration

Variable

BB14 is often used in vitro to stimulate neurite outgrowth. Doses are typically expressed as concentrations in cell culture media. Not directly translatable to human dosage without further in vivo validation.

Cognitive Enhancement (Experimental)

Unknown; extrapolation from animal data is unreliableUnknown
Duration

Unknown

Human dosing for cognitive enhancement is speculative. Animal studies suggest potential, but significant research is needed to establish safe and effective human protocols.

Timing & Frequency

Timing depends on the specific peptide and its pharmacokinetic properties. Some peptides, like hNGFp, exhibit rapid CNS activity following peripheral administration. Others may require more sustained exposure for optimal effects. Preclinical studies have used both single and repeated dosing regimens.

Cycle Guidance

Due to the experimental nature of NGF mimetic peptides, cycle guidance is largely based on precautionary principles. Given the potential for long-term receptor desensitization or other unknown effects, cycling may be considered. However, there is no established rationale or evidence base for specific cycle lengths.

Reconstitution Reference

Quick reference for reconstituting NGF Mimetic Peptides. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeVariable, typically 1-10 mg per vial
BAC Water Volume0.5-5 mL bacteriostatic water for desired concentration
Concentration & DrawAdjust water volume to achieve desired concentration. Example: 1 mg in 1 mL yields 1 mg/mL (1 mcg = 0.001 mL).
StorageRefrigerate at 2–8°C after reconstitution. Keep lyophilized powder at -20°C for long-term storage.
StabilityReconstituted solution stable up to 7-14 days refrigerated, depending on the peptide. Lyophilized powder stable 12-24 months at -20°C.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is a typical starting dose for hNGFp?
There is no established "typical" starting dose for hNGFp in humans. Preclinical studies have used doses ranging from 100–500 mcg/kg in animal models. Human experimentation should proceed with extreme caution and under strict medical supervision, starting with very low doses to assess tolerability.
How is BB14 administered?
BB14 is primarily used in vitro for research purposes. In vivo administration routes in animal studies have included subcutaneous and local application. Oral bioavailability is likely poor. Human administration is highly experimental.

Last updated: 2026-02-19